Female and Male Patients Achieve Similar Improvement, Outcomes, and Survivorship After Hip Arthroscopy With Labral and Capsular Repair for Femoroacetabular Impingement Syndrome at Minimum 10-Year Follow-Up.

PURPOSE: To evaluate the effect of patient sex on 10-year patient-reported outcomes (PROs) and survivorship after hip arthroscopy (HA) for femoroacetabular impingement syndrome (FAIS).

METHODS

Patients who underwent primary HA for FAIS with minimum 10-year follow-up from January 2012 to December 2013 were retrospectively reviewed. Female patients were propensity-matched to male patients in a 1:1 ratio by age and body mass index. PROs and rates of minimal clinically important difference (MCID) and patient-acceptable symptom state (PASS) achievement were compared between cohorts. Rate of reoperation-free survivorship was compared between sexes.

RESULTS

One hundred twenty-two female patients (age: 36.2 ± 12.3 years) were matched to 122 male patients (age: 35.7 ± 11.3 years, P = .594) at an average follow-up of 10.4 ± 0.4 years. There were no differences in any preoperative demographic characteristics between the groups (P ≥ .187). Both groups demonstrated significant improvement in every PRO measure between the preoperative and 10-year postoperative time points (P < .001). The magnitude of improvement was similar between the groups for all PRO measures (P ≥ .139). At 10 years, female patients trended toward greater MCID achievement for the Hip Outcome Score-Activities of Daily Living subscale than male patients (72.7% vs 57.3%, P = .061), with otherwise similar MCID achievement rates. Female patients trended toward significantly lower Hip Outcome Score-Sports Subscale PASS achievement (65.4% vs 77.1%, P = .121) with otherwise similar PASS achievement rates between the groups (P ≥ .170).

CONCLUSIONS

Female and male patients experienced similar improvement in PROs at 10-year follow-up. MCID and PASS achievement rates were predominantly similar between sexes. Survivorship did not differ between groups. Long-term success can be expected for appropriately indicated patients undergoing HA for FAIS, regardless of sex.

LEVEL OF EVIDENCE: Level III, retrospective cohort study.